Astria Therapeutics Inc 's ROA from the third quarter of 2025 to the third quarter of 2024 and 5 Year Period
Return on Assets, Quarterly Results, Trends, Rankings, Statistics
What is Astria Therapeutics Inc 's ROA in the third quarter of 2025?
Astria Therapeutics Inc recorded a cumulative net loss of $-124 million during 12 months ending in the third quarter of 2025, resulting in a negative return on assets (ROA) of -41.14%.
However, within the Healthcare sector 513 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the second quarter of 2025 from 3887 to 3916.
:Astria Therapeutics, Inc., a biopharmaceutical company, is forging a path towards revolutionizing treatments for allergic and immunologic diseases. The company recently announced promising results from two of its key clinical trials presented at high-profile European scientific congresses. These developments not only reinforce Astria s commitment to developing life-changing therapies but also highlight the potential for significant advancements in patient care. Astria Therapeutics, Inc. (NASDAQ: ATXS), renowned for its dedication to improving treatment outcomes in allergic and immunologic diseases, has made notable strides in its clinical trials involving monoclonal antibody therapies. The company has reported positive initial outcomes from its Phase 1a trial for STAR-0310, as well as promising data from the ALPHA-SOLAR long-term open-label trial evaluating Navenibart (STAR0215) in hereditary angioedema (HAE) patients. These findings were disseminated at the European Academy of Dermatology and Venereology (EADV) Congress and the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, respectively. STAR-0310 Phase 1a Trial:During the EADV Congress 2025, Astria Therapeutics shared the initial data from the Phase 1a trial of STAR-0310. STAR-0310 is a YTE half-life extended monoclonal antibody antagonist of OX40, developed to target allergic and immunologic diseases. The trial s data revealed that STAR-0310 achieved a best-in-class half-life of up to 68 days, suggesting the feasibility of biannual administration. Furthermore, the therapy demonstrated durable cytokine inhibition, positioning STAR-0310 as a potential game changer in its therapeutic class.
A Step Forward in Dermatology: Astria Therapeutics New Data Shines Light Amid Financial ChallengesAmidst the picturesque autumn landscapes of Paris, the 2025 European Academy of Dermatology and Venereology (EADV) Congress promises to draw together the world s leading dermatologists, venereologists, and innovators in healthcare. This year, a spotlight falls on Astria Therapeutics, Inc., a Boston-based biopharmaceutical company dedicated to pioneering advancements in allergic and immunologic diseases. Despite the financial turbulence that seems to have clouded the company s recent journey, an exciting shimmer of hope emerges with the upcoming presentation of their initial data from the Phase 1a trial of STAR-0310.Astria Therapeutics path, albeit fraught with notable fiscal challenges, demonstrates a resilient stride towards medical innovation. The firm recently reported a cumulative net loss of $117 million by the end of the second quarter of 2025. An unenviable figure, it underpins a negative return on assets (ROA) of -36.09%. In a competitive healthcare sector with 414 companies showing a higher ROA, Astria s ranking advanced remarkably within the June quarter, moving from 3514 to 3011 in overall standings. This progression, while modest, speaks volumes about Astria s tenacity in the face of adversity.
Astria Therapeutics, Inc. (Nasdaq: ATXS), a burgeoning player in the biopharmaceutical sector, is steering through a financially challenging period while executing strategic initiatives to bolster its future. The company, which is focused on developing innovative therapies for allergic and immunologic diseases, recently announced the issuance of inducement grants under the Nasdaq Listing Rule 5635(c)(4). This article examines the implications of these grants alongside Astria Therapeutics’ financial performance as of the close of 2024. Inducement Grants Overview On April 1, 2025, Astria Therapeutics granted stock options to purchase 43,650 shares of its common stock. These options were issued under the company’s 2022 Inducement Stock Incentive Plan, a mechanism designed specifically for individuals who are joining the company for the first time as employees. By leveraging such inducements, Astria aims to attract fresh talent capable of driving its RandD efforts towards life-changing therapies.
Boston-based Astria Therapeutics, Inc. (Nasdaq: ATXS), a pioneering biopharmaceutical company dedicated to developing groundbreaking therapies aimed at combating allergic and immunologic diseases, has recently made significant strides in its corporate strategy. This includes the strategic encouragement of top talent through inducement grants, advancements in clinical trials, and a robust financial performance update.On March 3, 2025, Astria Therapeutics announced the granting of stock options to purchase 87,450 shares of common stock as part of its 2022 Inducement Stock Incentive Plan. This plan is specifically tailored to reward individuals who were not previous employees of the company, reflecting Astria s commitment to attract skilled professionals to its innovative pipeline. The inducement grants align with Nasdaq Listing Rule 5635(c)(4), which regulates equity award grants to bolster corporate talent. Inducement grants have become increasingly vital for companies like Astria that are in the growth phase and seek to establish a robust human capital foundation to drive research and development activities.
BOSTON, October 2024 Astria Therapeutics, Inc. (NASDAQ:ATXS), a leading biopharmaceutical company focusing on the development of transformative therapies for allergic and immunologic diseases, announced its financial results for the third quarter ended September 30, 2024, alongside a comprehensive corporate update. Dr. Jill C. Milne, Chief Executive Officer of Astria Therapeutics, expressed her enthusiasm about the company’s recent progress, stating, “We had another strong quarter of execution for both navenibar and STAR-0310. Our team remains dedicated to creating innovative solutions for patients suffering from various allergic and immunologic conditions.” Financial Performance Highlights For the third quarter of 2024, Astria Therapeutics reported substantial advancements in key financial metrics that underscore the company s growth trajectory. Revenue spikes across various segments showcased the strong demand for their lead product candidates. Though specific figures were not disclosed in the press release, it was noted that revenue from corporate clients has experienced a notable increase.In earlier quarters, Astria’s financial performance remained stable, but the recent surge is indicative of improved market acceptance of navenibar, the company s flagship treatment. This new revenue influx reflects Astria’s successful efforts in enhancing its strategic partnerships within the biopharmaceutical sector.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
